- Home
- THW vs BCYC Comparison
THW vs BCYC Comparison
Compare THW & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THW | BCYC |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.7M | 476.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | THW | BCYC |
|---|---|---|
| Price | $12.85 | $6.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | 149.9K | ★ 237.0K |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 10.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.76 | $6.03 |
| 52 Week High | $14.89 | $13.66 |
Technical Indicators
Market Signals| Indicator | THW | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 52.55 |
| Support Level | $12.67 | $6.37 |
| Resistance Level | $13.03 | $7.34 |
| Average True Range (ATR) | 0.21 | 0.33 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 67.42 | 62.50 |
Price Performance
Historical ComparisonAbout THW abrdn World Healthcare Fund Shares of Beneficial Interest
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.